Segments - Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market by Therapeutic Areas (Oncology [Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Others], Neurological Disorders, Cardiovascular Disease, Immunological Disorders, and Others), Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global pharmacogenomics technology (theranostics and companion diagnostics) market size was valued at USD 6.20 Billion in 2022 and is likely reach to USD 13.14 Billion by 2031, expanding at a CAGR of 8.7% during the forecast period, 2023-2031. The growth of the market is attributed to the growing different initiatives from governments towards encouraging pharmacogenomics diagnostics.
Moreover, gradual development of new pharmacogenomics tests in emerging economies are playing major roles for the market expansion. Pharmacogenomics technology is widely adopted to innovate and modify drugs development so that these drugs can increase efficacy and safety for individual healthcare.
One of the key aspects for the implementation of the technology for the drugs development is to meet the needs of several drugs or medications from the population especially in developing regions. With the extensive study by researchers and scientists, several new diagnostics methods have been introduced that ensure high accuracy and effective in using various testing devices.
Additionally, factors such as the rapid development of advanced technology, the capacity to answer local requirements, effective implementation with a reasonable time span and cost-effective, the ability to decrease knowledge gap, and the capacity for secondary aids are key factors pushing the market expansion. Several pharmacogenomics studies are widely conducted by various players to increase the interaction and effects of drug development with respect to genes.
The study aims to understand how the inherited genes influence the way medications and treatments work on every individual. In general, the genetic study is extensively held as key steps to address several treatment methods but some major side-effects after the use of genetic treatment drugs pose challenges to the overall market expansion.
The COVID-19 pandemic has increased the importance of pharmacogenomics and several key pharmaceutical players have started focusing on the development of vaccine to curb the pandemic. Majority of researchers and scientists widely consider to use pharmacogenomic technology to learn about the coronavirus and develop vaccines, thereby increasing the market growth.
The report on the global pharmacogenomics technology (theranostics and companion diagnostics) market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Pharmacogenomics Technology Theranostics and Companion Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Therapeutic Areas (Oncology [Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Others], Neurological Disorders, Cardiovascular Disease, Immunological Disorders, and Others), and Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
Key Players Covered in the Report |
Qiagen NV; GE Healthcare; Agilent Technologies Inc; F.Hoffmann-La Roche AG; Foundation Medicine; Thermo Fisher Scientific Inc; Leica Biosystems Nussloch GmBH; and Pfizer |
Based on therapeutic areas, the global pharmacogenomics technology (theranostics and companion diagnostics) market is segmented into oncology, neurological disorders, cardiovascular disease, immunological disorders, and others. The oncology segment is further divided into lung cancer, breast cancer, colorectal cancer, cervical cancer, and others.
The oncology segment is expected to constitute a major share of the market during the forecast period owing to the possession of innovative technology that makes precision treatment, care effective, and affordable.
On the other hand, the immunological disorders segment is anticipated to grow at a rapid pace during the forecast period due to the rise in armamentarium therapies, which work on the basis of immunological diagnostics and treatments. These methods have been found in various medical applications including the treatment for tumors and cancer.
On the basis of technology, the market is divided into PCR, In-situ Hybridization, immunohistochemistry, sequencing, and others. The sequencing segment is expected to constitute a major share of the market during the forecast years owing to the increase in the volume of proof-of-concept diagnostics, studies and research particularly in next-generation sequence.
There has been a rapid progress in the development of NGS technology, data analysis, and the platform solutions that help propel rapidly with respect to this technique for research settings. This research is then carried out for the development of innovation for sequencing techniques giving rise to the new next-generation sequencing, thereby propelling the segment growth.
On the basis of regions, the global pharmacogenomics technology (theranostics and companion diagnostics) market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to expand at an impressive CAGR during the forecast period, 2023-2031.
This regional market growth can be attributed to the acceleration of research and development activities in various fields such as integrated medicine. There is also active participation of government and regulatory bodies encouraging the development of the pharmaceutical industry, which is projected to boost the market growth during the forecast period.
Major players competing in the global pharmacogenomics technology (theranostics and companion diagnostics) market are Qiagen NV; GE Healthcare; Agilent Technologies Inc; F.Hoffmann-La Roche AG; Foundation Medicine; Thermo Fisher Scientific Inc; Leica Biosystems Nussloch GmBH; and Pfizer.
Some of these players are engaging in proactive optimization be it in business mix or that of portfolios. These organizations are also involved in the development of theranostics which can target multiple effective drugs towards people. They are also involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
For instance, on 23 April 2021, F.Hoffmann-La Roche AG received the US Food and Drug Administration (FDA) approval for the very first companion diagnostics used for the identification of endometrial cancer patients.